Skip to main content

Table 2 Summary RRs and 95% CI

From: Innegligible musculoskeletal disorders caused by zoledronic acid in adjuvant breast cancer treatment: a meta-analysis

Complications

ZOL vs no ZOL

Upfront ZOL vs delayed ZOL

 

RR (95%CI)

P ⋆

Number of studies

RR (95%CI)

P ⋆

Number of studies

Arthralgia

1.162 (1.096-1.232) #

0.466

4

1.022 (0.932-1.120)

0.850

3

Bone pain

1.257 (1.149-1.376)

0.193

2

1.284 (1.135-1.453)

0.460

2

Muscle pain

1.198 (0.901-1.594)

0.366

2

1.071 (0.942-1.217)

0.422

3

  1. RR, risk ratio; CI, confidence interval; ZOL, zoledronic acid;
  2. *P value for between-study heterogeneity; #the number in AZURE trial included the number of arthralgia and muscle pain.
Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us